Esther M. Briganti

Esther M. Briganti

Auto-generated profile, based on publicly available information

Esther M. Briganti

Epworth Hospital, Melbourne, VIC

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2003 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SCSteven J. Chadban
Steven J. Chadban
EBEsther M. Briganti
Esther M. Briganti
PKPeter G. Kerr
Peter G. Kerr
DDDavid Dunstan
David Dunstan
TWTimothy A. Welborn
Timothy A. Welborn
RARobert C. Atkins
Robert C. Atkins
Article abstract Heart tissues of patients with PD or incidental Lewy body (LB) disease (ILBD) were examined by light and electron microscopy. LBs and α-synuclein–positive neurites were identified in the hearts from 9 of 11 patients with PD and from 7 of 7 patients with ILBD. LBs were present in both tyrosine hydroxylase-positive and -negative nerve processes, which are nerves of extrinsic sympathetic and intrinsic origin, respectively. These findings provide histologic evidence that the postganglionic sympathetic and intrinsic neurons in the heart are involved in the PD disease process.

11 July 2002 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EBEsther M. Briganti
Esther M. Briganti
GRGraeme R. Russ
Graeme R. Russ
JMJohn McNeil
John McNeil
RARobert C. Atkins
Robert C. Atkins
SCSteven J. Chadban
Steven J. Chadban
Recurrent glomerulonephritis is a known cause of renal allograft loss; however, the incidence of this complication is poorly defined. We determined the incidence, timing, and relative importance of allograft loss due to the recurrence of glomerulonephritis.

1 February 2005 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
RARobert C. Atkins
Robert C. Atkins
EBEsther M. Briganti
Esther M. Briganti
JLJulia B. Lewis
Julia B. Lewis
LHLawrence G. Hunsicker
Lawrence G. Hunsicker
GBGregory Braden
Gregory Braden
ELEdmund J. Lewis
Edmund J. Lewis

1 September 2003 in Menopause
Verified
Journal Article
Closed access
RGRebecca Goldstat
Rebecca Goldstat
EBEsther Briganti
Esther Briganti
JTJane Tran
Jane Tran
RWRory Wolfe
Rory Wolfe
SDSusan R. Davis
Susan R. Davis
Circulating testosterone in women declines during the late reproductive years such that otherwise healthy women in their 40s have approximately half the testosterone level as women in their 20s. Despite this, research showing the benefits of androgen replacement has been limited to the postmenopausal years. In view of the known premenopausal physiological decline in testosterone, we have evaluated the efficacy of transdermal testosterone therapy on mood, well-being, and sexual function in eugonadal, premenopausal women presenting with low libido. Premenopausal women with low libido participated in a randomized, placebo-controlled, crossover, efficacy study of testosterone cream (10 mg/day) with two double-blind, 12-week, treatment periods separated by a single-blind, 4-week, washout period. Thirty-four women completed the study per protocol, with 31 women (mean age 39.7 +/- 4.2 years; serum testosterone 1.07 + 0.50 nmol/L) providing complete data. Testosterone therapy resulted in statistically significant improvements in the composite scores of the Psychological General Well-Being Index [+12.9 (95% CI, +4.6 to +21.2), P = 0.003] and the Sabbatsberg Sexual Self-Rating Scale [+15.7 (95% CI, +6.5 to +25.0), P = 0.001] compared with placebo. A mean decrease in the Beck Depression Inventory score approached significance [-2.8 (95% CI, -5.7 to +0.1), P = 0.06]. Mean total testosterone levels during treatment were at the high end of the normal range, and estradiol was unchanged. No adverse effects were reported. Testosterone therapy improves well-being, mood, and sexual function in premenopausal women with low libido and low testosterone. As a substantial number of women experience diminished sexual interest and well-being during their late reproductive years, further research is warranted to evaluate the benefits and safety of longer-term intervention.

1 July 2001 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
EBEsther M. Briganti
Esther M. Briganti
JDJohn Dowling
John Dowling
MFMoira Finlay
Moira Finlay
PHPrue A. Hill
Prue A. Hill
CJColin L. Jones
Colin L. Jones
RARobert C. Atkins
Robert C. Atkins
Background. There is limited population‐based epidemiological data on renal disease. An insight into the spectrum of clinically significant glomerulonephritis can be obtained from renal biopsy diagnoses. This is a descriptive report of biopsy‐proven glomerulonephritis within a defined population. Methods. A retrospective review of the pathology reports of all native renal biopsies performed in the Australian state of Victoria in 1995 and 1997 was undertaken. Trends in the average annual age‐ and sex‐specific incidence rates for biopsy‐proven glomerulonephritis were calculated. Comparisons were made with the incidence of end‐stage renal disease due to glomerulonephritis confirmed on renal biopsy. Results. The most common glomerulonephritides in adults are IgA disease, focal glomerulosclerosis, lupus nephritis and vasculitis, and in children are lupus nephritis, focal glomerulosclerosis, IgA disease and minimal change disease. A male predominance is seen for all glomerulonephritides, except lupus nephritis, in both adults and children. An increase in incidence of disease with age, particularly in males, is seen for vasculitis and focal glomerulosclerosis. The most common glomerulonephritides on renal biopsy are reflected in the most common causes of end‐stage renal disease due to glomerulonephritis. Conclusions. This review has provided population‐based descriptive epidemiological data on clinically significant glomerulonephritis. This data provides important clues for further studies relating to the identification of risk factors for the various types of glomerulonephritis.

1 October 2002 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
EBEsther M. Briganti
Esther M. Briganti
PBPauline Branley
Pauline Branley
SCSteven J. Chadban
Steven J. Chadban
JSJonathan E. Shaw
Jonathan E. Shaw
JMJohn McNeil
John McNeil
RARobert C. Atkins
Robert C. Atkins